3-benzoyl dopamine has been researched along with Rheumatoid Arthritis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhafiz, A; Abdelhafiz, D; Baker, T; Glascow, DA | 1 |
| Alvarez, DF; Bock, AE; Iikuni, N; Kay, J; Rehman, M; Zhang, M; Zhang, W | 1 |
| Ascsillán, A; Bakó, E; Bánvölgyi, A; Csupor, D; Dembrovszky, F; Gunther, E; Hegyi, P; Kemény, LV; Lutz, E; Meznerics, FA; Nagy, G; Szabó, B | 1 |
| Fautrel, B; Hajage, D; Kossi, S; Marotte, H; Moysidou, GS; Tubach, F | 1 |
| Calabrese, LH | 1 |
2 review(s) available for 3-benzoyl dopamine and Rheumatoid Arthritis
| Article | Year |
|---|---|
Biomarkers for the diagnosis and treatment of rheumatoid arthritis - a systematic review.
Topics: 14-3-3 Proteins; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Humans; Prognosis | 2023 |
Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Humans; Severity of Illness Index | 2023 |
1 trial(s) available for 3-benzoyl dopamine and Rheumatoid Arthritis
| Article | Year |
|---|---|
Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Chronic Disease; Humans; Recurrence; Severity of Illness Index; Tumor Necrosis Factor Inhibitors | 2023 |
2 other study(ies) available for 3-benzoyl dopamine and Rheumatoid Arthritis
| Article | Year |
|---|---|
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
Topics: Adalimumab; Adult; Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Dopamine; Humans; Infliximab; Randomized Controlled Trials as Topic | 2022 |
MBDA: A Valuable Tool for Medical Decision Making.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Decision-Making; Dopamine; Humans | 2019 |